Flu Hospitalization Rate Week 19: Is 85-90 Already Locked In?

The CDC’s FluSurv-NET surveillance system tracks weekly influenza hospitalization rates with a precision that leaves little room for interpretation. Week 19 of 2026 is nearly settled, at least according to traders. The 85-90 hospitalizations-per-100,000 range is priced at 92.5% probability, a level of conviction that suggests the market treats this outcome as close to certain rather than contested.

Volume is thin. Total trading sits at $1,933 against $3,041 in available liquidity, which means this market has not attracted serious capital. Thin liquidity markets like this one can reprice sharply on a single large bet or an unexpected CDC data revision. The 92.5% number reflects strong directional consensus, but not deep institutional confidence.

How the Week Nineteen Flu Hospitalization Contract Works

This contract resolves based on the CDC’s official cumulative influenza hospitalization rate for Week 19 of the 2026 flu season. The CDC publishes these figures through FluView, its weekly influenza surveillance report. Resolution requires the published rate to fall within the 85-90 hospitalizations per 100,000 population range. The resolution date is May 22, 2026.

• 85-90 (YES): Priced at $0.93, implying 92.5% probability. This is the primary outcome traders are backing.
• 80-85: The next nearest band, representing a modest undershoot of current expectations.
• 90-95: The overshoot scenario, implying hospitalizations ran slightly hotter than the favored range.
• <80: A significant miss to the downside, requiring a sharp late-season decline.
• 95-100 and 100+: Tail risk scenarios representing a late-season surge well above current trajectory.

A miss on the 85-90 band requires the CDC’s Week 19 FluView report to land outside that range entirely. The flu season’s late-spring trajectory would need to either accelerate beyond 90 or drop below 85. Both directions face headwinds: late-season flu activity historically decelerates in May, and the cumulative rate is unlikely to spike sharply in a single week. Upside misses are possible if a late influenza B wave materialized in Week 19, but the market is assigning that scenario less than an 8% combined probability across all alternative outcomes.

Sponsored Partner

Momentum and Market Signals: Conviction Without Catalysts

The momentum composite, combining flat 1-hour and 24-hour price changes with a trend score of 20.00, reads as stable and directionless. No fresh catalyst has moved this contract in the past 24 hours. The most likely driver of any remaining price movement is the CDC FluView Week 19 publication, which typically releases on Fridays. The May 22 resolution date aligns closely with that publication window.

At $1,933 in total volume against $3,041 in liquidity, this market is operating well below the threshold where institutional signals carry weight. Volume under $10,000 means a single trader with $500 can shift the price meaningfully. The market is pricing uncertainty, not science, and right now there is very little uncertainty being priced in.

• 1h and 24h price change both read N/A: No trades have occurred in the recent window, confirming the market is in a holding pattern ahead of CDC publication.
• Liquidity at $3,041 exceeds volume at $1,933: This is an illiquid market with more available depth than actual trading interest, a signal that participation is minimal.
• Trend score of 20.00: Neutral, with no directional momentum building in either direction before resolution.
• Trader sentiment breakdown is 92.5% YES and 7.5% NO: Strong directional lean, but the small trader pool limits how much signal this carries.
• Resolution on May 22, 2026: One week away, with the CDC FluView report as the single event that determines this contract’s outcome.

Lines Analysis: What the CDC Data Needs to Show

FluSurv-NET cumulative rates in late spring 2026 have been tracking within a range consistent with a moderate flu season. Week 19 typically represents the tail end of flu season activity, where cumulative rates stabilize rather than accelerate. The 85-90 band reflects a hospitalization burden consistent with a moderate-to-high flu season, not an outlier year in either direction.

The scenario where this contract misses is narrow but real. A late influenza B resurgence, which can occur even as influenza A activity winds down, could push the Week 19 cumulative rate above 90. Alternatively, if Week 18 data already anchored the cumulative rate closer to 84 or 85, rounding and revision effects could pull the published figure below the 85-90 floor. CDC FluView figures are occasionally revised in subsequent weeks, but resolution will be based on the figure published at the time of the May 22 deadline.

Signals to monitor before May 22:

• CDC FluView Week 19 publication, expected Friday May 16 or the following Friday May 23, which will be the definitive resolution input for this contract.
• Any CDC statement on late-season influenza B activity, which remains the primary upside risk to the 85-90 band.
• State-level hospitalization data from health departments in high-burden states, which can serve as a leading indicator before federal FluView publishes.
• CDC FluSurv-NET preliminary estimates, which sometimes circulate before the official FluView weekly report is finalized.
• Week 18 finalized cumulative rate, which sets the baseline from which Week 19 will be measured and published.

The $1,933 in trading volume does not suggest sophisticated capital has done deep analysis here. The 92.5% price reflects a reasonable read of late-season flu trajectory, but the thin market means the price is more about absence of opposition than presence of conviction. The data favors the 85-90 outcome based on seasonal norms, but this is exactly the kind of market where a single CDC data point can reprice everything in minutes.

LINES VERDICT

Likely Confirmed, Pending CDC Publication

The 85-90 band aligns with a moderate flu season’s expected late-spring cumulative rate, and no current data signal suggests a significant deviation in either direction before the May 22 resolution date.

What the market says: At 92.5%, traders have priced this as nearly settled. The thin volume below $2,000 means this confidence is fragile, and a single unexpected CDC revision before May 22 could shift the price quickly.

Key unknown: The CDC FluView Week 19 report, expected in the days immediately before the May 22 resolution deadline, is the only data release that matters. If that report lands outside the 85-90 range, this market reprices immediately.

Scientific Context

CDC FluSurv-NET tracks laboratory-confirmed influenza hospitalizations across a network of hospitals in 13 states, extrapolated to national estimates. The cumulative rate is a running total from the start of flu season, meaning Week 19 figures reflect the entire season’s burden, not just a single week’s activity. Moderate flu seasons in recent years have produced cumulative hospitalization rates in the 70-100 per 100,000 range by late spring. The 85-90 band sits squarely in the historical middle of that range for a season without an exceptional outbreak or an unusually mild winter. What would move this market before May 22 is a FluView report landing outside that band, which would require either a late-season surge or a downward revision to prior weeks’ figures.

Frequently Asked Questions

• What does 92.5% probability mean here? It means traders collectively believe there is roughly a 92.5% chance the CDC’s FluView Week 19 report will show a cumulative hospitalization rate between 85 and 90 per 100,000. It is not a guarantee.
• What happens to the NO contract? The NO side, priced at $0.08, pays out if the CDC Week 19 cumulative rate lands outside the 85-90 range in any direction, including below 85 or above 90.
• What data release moves this market? The CDC FluView weekly report, published on Fridays, is the single most important input. The Week 19 edition will almost certainly determine how this contract resolves.
• When does this contract resolve? Resolution is set for May 22, 2026, which aligns with the expected CDC FluView Week 19 publication window.
• Is the volume reliable? At $1,933 in total volume, this is a very thin market. Prices can shift significantly on a single trade, and the 92.5% probability reflects limited participation rather than deep analytical consensus.

This analysis reflects market conditions as of May 15, 2026. Prediction market probabilities are volatile and shift as new data and regulatory decisions emerge, especially as the May 22, 2026 resolution date approaches. Lines.com does not accept bets or provide financial or gambling advice. All market outcomes are uncertain.